Tetraspanins as regulators of the tumour microenvironment: Implications for metastasis and therapeutic strategies

British Journal of Pharmacology

Volumn 171, Issue 24, 2014, Pages 5462-5490

  Detchokul, S ^a   Williams, E D ^a,b,c   Parker, M W ^d,e   Frauman, A G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d St Vincent's Public Hospital   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD151 ANTIGEN; CD33 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; INTEGRIN; TETRASPANIN; TETRASPANIN 1; TETRASPANIN 10; TETRASPANIN 11; TETRASPANIN 12; TETRASPANIN 13; TETRASPANIN 14; TETRASPANIN 15; TETRASPANIN 16; TETRASPANIN 18; TETRASPANIN 19; TETRASPANIN 2; TETRASPANIN 22; TETRASPANIN 23; TETRASPANIN 25; TETRASPANIN 26; TETRASPANIN 3; TETRASPANIN 4; TETRASPANIN 5; TETRASPANIN 6; TETRASPANIN 7; TETRASPANIN 8; TETRASPANIN 9; UNCLASSIFIED DRUG; UROPLAKIN 1A; UROPLAKIN 1B;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CELL ADHESION; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CORRELATIONAL STUDY; CYTOSKELETON; DRUG TARGETING; EXOSOME; HUMAN; LYMPHANGIOGENESIS; METASTASIS; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; CELL MEMBRANE; CELL MOTION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; METABOLISM;

ANTIGENS, CD151; CELL ADHESION; CELL MEMBRANE; CELL MOVEMENT; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; NEOPLASM METASTASIS; TETRASPANINS; TUMOR MICROENVIRONMENT;

EID: 84919329747     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12260     Document Type: Review

References (362)

1. Abe M, Sugiura T, Takahashi M, Ishii K, Shimoda M, Shirasuna K, (2008). A novel function of CD82/KAI-1 on E-cadherin-mediated homophilic cellular adhesion of cancer cells. Cancer Lett 266: 163-170.
2. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M, (1996). Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 56: 1751-1755.
3. Andre F, Schartz NEC, Movassagh M, Flament C, Pautier P, Morice P, et al. (2002). Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360: 295-305.
4. Ang J, Lijovic M, Ashman LK, Kan K, Frauman AG, (2004). CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Cancer Epidemiol Biomarkers Prev 13: 1717-1721.
5. Ang J, Fang BL, Ashman LK, Frauman AG, (2010). The migration and invasion of human prostate cancer cell lines involves CD151 expression. Oncol Rep 24: 1593-1597.
6. Arencibia JM, Martin S, Perez-Rodriguez FJ, Bonnin A, (2009). Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer. Int J Oncol 34: 457-463.
7. Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, et al. (2005). Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 174: 539-546.
8. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. (2006). A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12: 1260-1269.
9. Avraamides CJ, Garmy-Susini B, Varner JA, (2008). Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604-617.
10. Bailey RL, Herbert JM, Khan K, Heath VL, Bicknell R, Tomlinson MG, (2011). The emerging role of tetraspanin microdomains on endothelial cells. Biochem Soc Trans 39: 1667-1673.
11. Baleato RM, Guthrie PL, Gubler MC, Ashman LK, Roselli S, (2008). Deletion of Cd151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane. Am J Pathol 173: 927-937.
12. Bari R, Zhang YH, Zhang F, Wang NX, Stipp CS, Zheng JJ, et al. (2009). Transmembrane interactions are needed for KAI1/CD82-mediated suppression of cancer invasion and metastasis. Am J Pathol 174: 647-660.
13. Bari R, Guo Q, Xia B, Zhang YH, Giesert EE, Levy S, et al. (2011). Tetraspanins regulate the protrusive activities of cell membrane. Biochem Biophys Res Commun 415: 619-626.
14. Barreiro O, Zamai M, Yáñez-Mõ M, Tejera E, Lõpez-Romero P, Monk PN, et al. (2008). Endothelial adhesion receptors are recruited to adherent leukocytes by inclusion in preformed tetraspanin nanoplatforms. J Cell Biol 183: 527-542.
15. Bascom RA, García-Heras J, Hsieh CL, Gerhard DS, Jones C, Francke U, et al. (1992). Localization of the photoreceptor gene ROM1 to human chromosome 11 and mouse chromosome 19: sublocalization to human 11q13 between PGA and PYGM. Am J Hum Genet 51: 1028-1035.
16. Bascom RA, Liu L, Heckenlively JR, Stone EM, Mcinnes RR, (1995). Mutation analysis of the ROM1 gene in retinitis pigmentosa. Hum Mol Genet 4: 1895-1902.
17. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109-119.
18. Bass R, Werner F, Odintsova E, Sugiura T, Berditchevski F, Ellis V, (2005). Regulation of urokinase receptor proteolytic function by the tetraspanin CD82. J Biol Chem 280: 14811-14818.
19. Bassani S, Cingolani LA, (2012). Tetraspanins: interactions and interplay with integrins. Int J Biochem Cell Biol 44: 703-708.
20. Berditchevski F, (2001). Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 114: 4143-4151.
21. Berditchevski F, Odintsova E, (1999). Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signalling. J Cell Biol 146: 477-492.
22. Berditchevski F, Odintsova E, (2007). Tetraspanins as regulators of protein trafficking. Traffic 8: 89-96.
23. Berditchevski F, Zutter MM, Hemler ME, (1996). Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins). Mol Biol Cell 7: 193-207.
24. Berditchevski F, Gilbert E, Griffiths MR, Fitter S, Ashman L, Jenner SJ, (2001). Analysis of the CD151 center dot alpha(3)beta(1) integrin and CD151 center dot tetraspanin interactions by mutagenesis. J Biol Chem 276: 41165-41174.
25. Bienstock RJ, Barrett JC, (2001). KAI1, A prostate metastasis suppressor: prediction of solvated structure and interactions with binding partners; integrins, cadherins, and cell-surface receptor proteins. Mol Carcinog 32: 139-153.
26. Bijman MNA, van Berkel MPA, van Nieuw Amerongen GP, Boven E, (2008). Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility. Biochem Pharmacol 76: 707-716.
27. Blain JC, Mok Y-F, Kubanek J, Allingham JS, (2010). Two molecules of lobophorolide cooperate to stabilize an actin dimer using both their 'ring' and 'tail' region. Chem Biol 17: 802-807.
28. Boismenu R, Rhein M, Fischer WH, Havran WL, (1996). A role for CD81 in early T cell development. Science 271: 198-200.
29. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R, (2002). Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 5: 123-127.
30. Borghi N, Lowness M, Maruthamuthu V, Gardel ML, Nelson WJ, (2010). Regulation of cell motile behavior by crosstalk between cadherin- and integrin-mediated adhesions. Proc Natl Acad Sci U S A 107: 13199-13200.
31. Borre M, Offersen BV, Nerstrom B, Overgaard J, (1998). Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78: 940-944.
32. Boucheix C, Rubinstein E, (2001). Tetraspanins. Cell Mol Life Sci 58: 1189-1205.
33. Boucheix C, Soria C, Mirshahi M, Soria J, Perrot JY, Fournier N, et al. (1983). Characteristics of platelet aggregation induced by the monoclonal antibody ALB6 (acute lymphoblastic leukemia antigen p 24): inhibition of aggregation by ALB6Fab. FEBS Lett 161: 289-295.
34. Boucheix C, Duc GHT, Jasmin C, Rubinstein E, (2001). Tetraspanins and malignancy. Expert Rev Mol Med 1: 1-17.
35. Boyer B, Valles AM, Edme N, (2000). Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 60: 1091-1099.
36. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fassler R, (2002). Integrins in invasive growth. J Clin Invest 109: 999-1006.
37. Brockbank EC, Bridges J, Marshall CJ, Sahai E, (2005). Integrin beta 1 is required for the invasive behaviour but not proliferation of squamous cell carcinoma cells in vivo. Br J Cancer 92: 102-112.
38. Buim MEC, Lourenço SV, Carvalho KC, Cardim R, Pereira C, Carvalho AL, et al. (2010). Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma. Oral Oncol 46: 166-171.
39. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L, (2010). Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 78: 838-848.
40. Carmeliet P, Jain RK, (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
41. Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M, (1999). Identification of a family of human F-box proteins. Curr Biol 9: 1177-1179.
42. Cha JH, Brooke JS, Ivey KN, Eidels L, (2000). Cell surface monkey CD9 antigen is a coreceptor that increases diphtheria toxin sensitivity and diphtheria toxin receptor affinity. J Biol Chem 275: 6901-6907.
43. Chaffer CL, Thompson EW, Williams ED, (2007). Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 185: 7-19.
44. Chambrion C, Le Naour F, (2010). The tetraspanins CD9 and CD81 regulate CD9P1-induced effects on cell migration. PLoS ONE 5: e11219.
45. Chauhan SC, Vinayek N, Maher DM, Bell MC, Dunham KA, Koch MD, et al. (2007). Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy. J Histochem Cytochem 55: 867-875.
46. Chen H, Dziuba N, Friedrich B, Lindern JV, Murray JL, Rojo DR, et al. (2008a). A critical role for CD63 in HIV replication and infection of macrophages and cell lines. Virology 379: 191-196.
47. Chen L, Yuan D, Wang GL, Wang Y, Wu YY, Zhu J, (2010a). Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma. J Korean Med Sci 25: 1438-1442.
48. Chen L, Li X, Wang G-L, Wang Y, Zhu Y-Y, Zhu J, (2008b). Clinicopathological significance of overexpression of TSPAN1, Ki67 and CD34 in gastric carcinoma. Tumori 94: 531-538.
49. Chen L, Zhu Y-Y, Zhang X-J, Wang G-L, Li X-Y, He S, et al. (2009). TSPAN1 protein expression: a significant prognostic indicator for patients with colorectal adenocarcinoma. World J Gastroenterol 15: 2270-2276.
50. Chen L, Yuan D, Zhao R, Li H, Zhu J, (2010b). Suppression of TSPAN1 by RNA interference inhibits proliferation and invasion of colon cancer cells in vitro. Tumori 96: 744-750.
51. Chen L, Zhu YY, Li H, Wang GL, Wu YY, Lu YX, et al. (2010c). Knockdown of TSPAN1 by RNA silencing and antisense technique inhibits proliferation and infiltration of human skin squamous carcinoma cells. Tumori 96: 289-295.
52. Chen SL, Sun YX, Jin ZG, Jing XH, (2011a). Functional and biochemical studies of CD9 in fibrosarcoma cell line. Mol Cell Biochem 350: 89-99.
53. Chen Z, Mustafa T, Trojanowicz B, Brauckhoff M, Gimm O, Schmutzler C, et al. (2004). CD82, and CD63 in thyroid cancer. Int J Mol Med 14: 517-527.
54. Chen Z, Gu S, Trojanowicz B, Liu N, Zhu G, Dralle H, et al. (2011b). Down-regulation of TM4SF is associated with the metastatic potential of gastric carcinoma TM4SF members in gastric carcinoma. World J Surg Oncol 9. doi: 10.1186/1477-7819-9-4.
55. Chiyomaru T, Tatarano S, Kawakami K, Enokida H, Yoshino H, Nohata N, et al. (2011). SWAP70, actin-binding protein, function as an oncogene targeting tumor suppressive miR-145 in prostate cancer. Prostate 71: 1559-1567.
56. Chometon G, Zhang Z, Rubinstein E, Boucheix C, Mauch C, Aumailley M, (2006). Dissociation of the complex between CD151 and laminin-binding integrins permits migration of epithelial cells. Exp Cell Res 312: 983-995.
57. Clark KL, Oelke A, Johnson ME, Eilert KD, Simpson PC, Todd SC, (2004). CD81 associates with 14-3-3 in a redox-regulated palmitoylation-dependent manner. J Biol Chem 279: 19401-19406.
58. Cress AE, Rabinovitz I, Zhu WG, Nagle RB, (1995). The alpha-6-beta-1 and alpha-6-beta-4 integrins in human prostate-cancer progression. Cancer Metastasis Rev 14: 219-228.
59. Dang Z, Yagi K, Oku Y, Kouguchi H, Kajino K, Watanabe J, et al. (2009). Evaluation of Echinococcus multilocularis tetraspanins as vaccine candidates against primary alveolar echinococcosis. Vaccine 27: 7339-7345.
60. Davis ID, Cebon JS, (2011). Developing cancer immunotherapies. Asia Pac J Clin Oncol 7: 9-13.
61. De Bruyne E, Andersen TL, De Raeve H, Van Valckenborgh E, Caers J, Van Camp B, et al. (2006). Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients. Leukemia 20: 1870-1879.
62. Deng X, Li Q, Hoff J, Novak M, Yang H, Jin H, et al. (2012). Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis. Neoplasia 14: 678-689.
63. Denzer K, Kleijmeer MJ, Heijnen HFG, Stoorvogel W, Geuze HJ, (2000). Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113: 3365-3374.
64. Detchokul S, Frauman AG, (2011). Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol 71: 157-174.
65. Devbhandari RP, Shi G-M, Ke A-W, Wu F-Z, Huang X-Y, Wang X-Y, et al. (2011). Profiling of the tetraspanin CD151 web and conspiracy of CD151/integrin β1 complex in the progression of hepatocellular carcinoma. PLoS ONE 6: e24901.
66. Dietrich T, Onderka J, Bock F, Kruse FE, Vossmeyer D, Stragies R, et al. (2007). Inhibition of inflammatory lymphangiogenesis by integrin alpha 5 blockade. Am J Pathol 171: 361-372.
67. Dominguez-Jimenez C, Yanez-Mo M, Carreira A, Tejedor R, Gonzalez-Amaro R, Alvarez V, et al. (2001). Involvement of alpha 3 integrin/tetraspanins complexes in the angiogenic response induced by angiotensin II. FASEB J 15: 1457-1459.
68. Dong J, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. (1995). KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268: 884-886.
69. Donoso LA, Folberg R, Edelberg K, Arbizo V, Atkinson B, Herlyn M, (1985). Tissue distribution and biochemical properties of an ocular melanoma-associated antigen. J Histochem Cytochem 33: 1190-1196.
70. Donoso LA, Felberg NT, Edelberg K, Borlinghaus P, Herlyn M, (1986). Metastatic uveal melanoma: an ocular melanoma associated antigen in the serum of patients with metastatic disease. J Immunoassay 7: 273-283.
71. Dornier E, Coumailleau F, Ottavi JF, Moretti J, Boucheix C, Mauduit P, et al. (2012). TspanC8 tetraspanins regulate ADAM10/Kuzbanian trafficking and promote Notch activation in flies and mammals. J Cell Biol 199: 481-496.
72. Draber P, Vonkova I, Stepanek O, Hrdinka M, Kucova M, Skopcova T, et al. (2011). SCIMP, a transmembrane adaptor protein involved in major histocompatibility complex class II signaling. Mol Cell Biol 31: 4550-4562.
73. Dryja TP, Hahn LB, Kajiwara K, Berson EL, (1997). Dominant and digenic mutations in the peripherin/RDS and ROM1 genes in retinitis pigmentosa. Invest Ophthalmol Vis Sci 38: 1972-1982.
74. Duffield A, Kamsteeg EJ, Brown AN, Pagel P, Caplan MJ, (2003). The tetraspanin CD63 enhances the internalization of the H,K-ATPase beta-subunit. Proc Natl Acad Sci U S A 100: 15560-15565.
75. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ, (1998). Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 273: 20121-20127.
76. Esposito CL, Passaro D, Longobardo I, Condorelli G, Marotta P, Affuso A, et al. (2011). A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE 6: e24071.
77. Farokhzad OC, Jon SY, Khademhosseini A, Tran TNT, LaVan DA, Langer R, (2004). Nanopartide-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64: 7668-7672.
78. FDA (2003). FDA label information for Gleevec, Vol. 2012: FDA.
79. FDA (2004). FDA label information for Avastin, Vol. 2012: FDA.
80. FDA (2005). FDA label information for Nexavar, Vol. 2012: FDA.
81. FDA (2006). FDA label information for Sutent, Vol. 2012: FDA.
82. FDA (2009a). FDA label information for Votrient, Vol. 2012: FDA.
83. FDA (2009b). FDA label information of Afinitor, Vol. 2012: FDA.
84. FDA (2010). FDA label information of Provenge: FDA.
85. Fei Y, Wang J, Liu W, Zuo H, Qin J, Wang D, et al. (2012). CD151 promotes cancer cell metastasis via integrins α3β1 and α6β1 in vitro. Mol Med Rep 6: 1226-1230.
86. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, et al. (2001). Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 98: 1853-1858.
87. Fenteany G, Zhu S, (2003). Small-molecule inhibitors of actin dynamics and cell motility. Curr Top Med Chem 3: 593-616.
88. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, et al. (1998). Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51: 161-167.
89. Fidler IJ, (2002). The organ microenvironment and cancer metastasis. Differentiation 70: 498-505.
90. Fitter S, Seldin MF, Ashman LK, (1998). Characterisation of the mouse homologue of CD151 (PETA-3/SFA-1); genomic structure, chromosomal localisation and identification of 2 novel splice forms. Biochim Biophys Acta 1398: 75-85.
91. Fojo T, (2006). Can mutations in γ-actin modulate the toxicity of microtubule targeting agents? J Natl Cancer Inst 98: 1345-1347.
92. Friedl P, Gilmour D, (2009). Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 10: 445-457.
93. Friedl P, Wolf K, (2010). Plasticity of cell migration: a multiscale tuning model. J Cell Biol 188: 11-19.
94. Funakoshi T, Tachibana I, Hoshida Y, Kimura H, Takeda Y, Kijima T, et al. (2003). Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 22: 674-687.
95. Furuya M, Kato F, Nishimura N, Ishiwata I, Ikeda H, Ito R, et al. (2005). Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta 1 integrin subsets. Cancer Res 65: 2617-2625.
96. Garmy-Susini B, Avraamides CJ, Schmid MC, Foubert P, Ellies LG, Barnes L, et al. (2010). Integrin alpha 4 beta 1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res 70: 3042-3051.
97. Gartlan KH, Belz GT, Tarrant JM, Minigo G, Katsara M, Sheng KC, et al. (2010). A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity. J Immunol 185: 3158-3166.
98. Gesierich S, Berezovskiy I, Ryschich E, Zöller M, (2006). Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res 66: 7083-7094.
99. Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, et al. (2005). Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res 11: 2840-2852.
100. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. (2011). Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91: 1071-1121.
101. Golias C, Charalabopoulos A, Stagikas D, Giannakopoulos X, Pescho D, Batistatou A, et al. (2007). Molecular profiling and genomic microarrays in prostate cancer. Exp Oncol 29: 82-84.
102. Greco C, Bralet MP, Ailane N, Dubart-Kupperschmitt A, Rubinstein E, Le Naour F, et al. (2010). E-cadherin/p120-catenin and tetraspanin Co-029 cooperate for cell motility control in human colon carcinoma. Cancer Res 70: 7674-7683.
103. Green LR, Monk PN, Partridge LJ, Morris P, Gorringe AR, Read RC, (2011). Cooperative role for tetraspanins in adhesin-mediated attachment of bacterial species to human epithelial cells. Infect Immun 79: 2241-2249.
104. Guo Q, Xia B, Zhang F, Richardson MM, Li M, Zhang JS, et al. (2012). Tetraspanin CO-029 inhibits colorectal cancer cell movement by deregulating cell-matrix and cell-cell adhesions. PLoS ONE 7: e38464.
105. Gustafson-Wagner E, Stipp CS, (2013). The CD9/CD81 tetraspanin complex and tetraspanin CD151 regulate alpha3beta1 integrin-dependent tumor cell behaviors by overlapping but distinct mechanisms. PLoS ONE 8: e61834.
106. Haeuw JF, Goetsch L, Bailly C, Corvaia N, (2011). Tetraspanin CD151 as a target for antibody-based cancer immunotherapy. Biochem Soc Trans 39: 553-558.
107. Haining EJ, Yang J, Bailey RL, Khan K, Collier R, Tsai S, et al. (2012). The TspanC8 subgroup of tetraspanins interacts with A disintegrin and metalloprotease 10 (ADAM10) and regulates its maturation and cell surface expression. J Biol Chem 287: 39753-39765.
108. Hao S, Moyana T, Xiang J, (2007). Cancer immunotherapy by exosome-based vaccines. Cancer Biother Radiopharm 22: 692-703.
109. Hasegawa H, Nomura T, Kishimoto K, Yanagisawa K, Fujita S, (1998). SFA-1/PETA-3 (CD151), a member of the transmembrane 4 superfamily, associates preferentially with α5β1 integrin and regulates adhesion of human T cell leukemia virus type 1- infected T cell to fibronectin. J Immunol 161: 3087-3095.
110. Hasegawa M, Furuya M, Kasuya Y, Nishiyama M, Sugiura T, Nikaido T, et al. (2007). CD151 dynamics in carcinoma-stroma interaction: integrin expression, adhesion strength and proteolytic activity. Lab Invest 87: 882-892.
111. Hashida H, Takabayashi A, Tokuhara T, Hattori N, Taki T, Hasegawa H, et al. (2003). Clinical significance of transmembrane 4 superfamily in colon cancer. Br J Cancer 89: 158-167.
112. Hassuna N, Monk PN, Moseley GW, Partridge LI, (2009). Strategies for targeting tetraspanin proteins. BioDrugs 23: 341-359.
113. Hato T, Ikeda K, Yasukawa M, Watanabe A, Kobayashi Y, (1988). Exposure of platelet fibrinogen receptors by a monoclonal antibody to CD9 antigen. Blood 72: 224-229.
114. Hege KM, Jooss K, Pardoll D, (2006). GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 25: 321-352.
115. Heikens MJ, Cao TM, Morita C, DeHart SL, Tsai S, (2007). Penumbra encodes a novel tetraspanin that is highly expressed in erythroid progenitors and promotes effective erythropoiesis. Blood 109: 3244-3252.
116. Hemler ME, (2001). Specific tetraspanin functions. J Cell Biol 155: 1103-1107.
117. Hemler ME, (2005). Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6: 801-811.
118. Hemler ME, (2008). Targeting of tetraspanin proteins-potential benefits and strategies. Nat Rev Drug Discov 7: 747-758.
119. Hemler ME, Mannion BA, Berditchevski F, (1996). Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta 1287: 67-71.
120. Hicke BJ, Stephens AW, (2000). Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest 106: 923-928.
121. Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, et al. (2010). Sipuleucel-T. Nat Rev Drug Discov 9: 513-514.
122. Higashiyama M, Doi O, Kodama K, Yokouchi H, Adachi M, Huang C-L, et al. (1997). Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 74: 205-211.
123. Higginbottom A, Takahashi Y, Bolling L, Coonrod SA, White JM, Partridge LJ, et al. (2003). Structural requirements for the inhibitory action of the CD9 large extracellular domain in sperm/oocyte binding and fusion. Biochem Biophys Res Commun 311: 208-214.
124. Hirano C, Nagata M, Noman AA, Kitamura N, Ohnishi M, Ohyama T, et al. (2009). Tetraspanin gene expression levels as potential biomarkers for malignancy of gingival squamous cell carcinoma. Int J Cancer 124: 2911-2916.
125. von Hofe E, (2011). A new ally against cancer. Sci Am 305: 66-70.
126. Hong H, Goel S, Zhang Y, Cai W, (2011). Molecular imaging with nucleic acid aptamers. Curr Med Chem 18: 4195-4205.
127. Hong I, Jin Y, Byun H, Jeoung D, Kim Y, Lee H, (2006). Homophilic interactions of tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathway. J Biol Chem 281: 24279-24292.
128. Hong IK, Kim YM, Jeoung DI, Kim KC, Lee H, (2005). Tetraspanin CD9 induces MMP-2 expression by activating p38 MAPK, JNK and c-Jun pathways in human melanoma cells. Exp Mol Med 37: 230-239.
129. Hong IK, Jeoung DI, Ha KS, Kim YM, Lee H, (2012). Tetraspanin CD151 stimulates adhesion-dependent activation of Ras, Rac, and Cdc42 by facilitating molecular association between β1 integrins and small GTPases. J Biol Chem 287: 32027-32039.
130. Hong YK, Lange-Asschenfeldt B, Velasco P, Hirakawa S, Kunstfeld R, Brown LF, et al. (2004). VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J 18: 1111-1113.
131. Hood JD, Cheresh DA, (2002). Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91-100.
132. Hori H, Yano SJ, Koufuji K, Takeda J, Shirouzu K, (2004). CD9 expression in gastric cancer and its significance. J Surg Res 117: 208-215.
133. Houle CD, Ding X-Y, Foley JF, Afshari CA, Barrett JC, Davis BJ, (2002). Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol 86: 69-78.
134. Hu CCA, Liang FX, Zhou G, Tu L, Tang CHA, Zhou J, et al. (2005). Assembly of urothelial plaques: tetraspanin function in membrane protein trafficking. Mol Biol Cell 16: 3937-3950.
135. Huang CL, Taki T, Adachi M, Yagita M, Sawada S, Takabayashi A, et al. (1997). MRP-1/CD9 and KAI1/CD82 expression in normal and various cancer tissues. Int J Oncol 11: 1045-1051.
136. Huang CL, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M, (1998). Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 153: 973-983.
137. Huang H, Sossey-Alaoui K, Beachy SH, Geradts J, (2007). The tetraspanin superfamily member NET-6 is a new tumor suppressor gene. J Cancer Res Clin Oncol 133: 761-769.
138. Huang XY, Ke AW, Shi GM, Ding ZB, Devbhandari RP, Gu FM, et al. (2010). Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients. Cancer 116: 5440-5451.
139. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. (2007). Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383.
140. Huttenlocher A, Horwitz AR, (2011). Integrins in cell migration. Cold Spring Harb Perspect Biol 3: a005074.
141. Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M, (1993). Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 177: 1231-1237.
142. Imai K, Takaoka A, (2006). Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714-727.
143. Imai T, Fukudome K, Takagi S, Nagira M, Furuse M, Fukuhara N, et al. (1992). C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. J Immunol 149: 2879-2886.
144. Inoue G, Horiike N, Onji M, (2001). The CD81 expression in liver in hepatocellular carcinoma. Int J Mol Med 7: 67-71.
145. Ishibashi T, Ding L, Ikenaka K, Inoue Y, Miyado K, Mekada E, et al. (2004). Tetraspanin protein CD9 is a novel paranodal component regulating paranodal junctional formation. J Neurosci 24: 96-102.
146. Ivaska J, Whelan RDH, Watson R, Parker PJ, (2002). PKCε controls the traffic of β1 integrins in motile cells. EMBO J 21: 3608-3619.
147. Iwai K, Ishii M, Ohshima S, Miyatake K, Saeki Y, (2007). Expression and function of transmembrane-4 superfamily (tetraspanin) proteins in osteoclasts: reciprocal roles of tspan-5 and NET-6 during osteoclastogenesis. Allergol Int 56: 457-463.
148. Iwata S, Kobayashi H, Miyake-Nishijima R, Sasaki T, Souta-Kuribara A, Nori M, et al. (2002). Distinctive signaling pathways through CD82 and beta 1 integrins in human T cells. Eur J Immunol 32: 1328-1337.
149. Jang HI, Lee H, (2003). A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med 35: 317-323.
150. Jee BK, Lee JY, Lim Y, Lee KH, Jo Y-H, (2007). Effect of KAI1/CD82 on the β1 integrin maturation in highly migratory carcinoma cells. Biochem Biophys Res Commun 359: 703-708.
151. Jin H, Varner J, (2004). Integrins: roles in cancer development and as treatment targets. Br J Cancer 90: 561-565.
152. Johnson JL, Winterwood N, DeMali KA, Stipp CS, (2009). Tetraspanin CD151 regulates RhoA activation and the dynamic stability of carcinoma cell-cell contacts. J Cell Sci 122: 2263-2273.
153. Jones A, Fujiyama C, (1999). Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int 83: 535-556.
154. Junge HJ, Yang S, Burton JB, Paes K, Shu X, French DM, et al. (2009). TSPAN12 regulates retinal vascular development by promoting norrin- but not Wnt-induced FZD4/β-catenin signaling. Cell 139: 299-311.
155. Kamisasanuki T, Tokushige S, Terasaki H, Khai NC, Wang Y, Sakamoto T, et al. (2011). Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy. Biochem Biophys Res Commun 413: 128-135.
156. Kanetaka K, Sakamoto M, Yamamoto Y, Yamasaki S, Lanza F, Kanematsu T, et al. (2001). Overexpression of tetraspanin CO-029 in hepatocellular carcinoma. J Hepatol 35: 637-642.
157. Kaprielian Z, Patterson PH, (1993). Surface and cytoskeletal markers of rostrocaudal position in the mammalian nervous system. J Neurosci 13: 2495-2508.
158. Karamatic Crew V, Burton N, Kagan A, Green CA, Levene C, Flinter F, et al. (2004). CD151, the first member of the tetraspanin (TM4) superfamily detected on erythrocytes, is essential for the correct assemly of human basement membranes in kidney and skin. Blood 104: 2217-2223.
159. Kazarov AR, Yang XW, Stipp CS, Sehgal B, Hemler ME, (2002). An extracellular site on tetraspanin CD151 determines alpha 3 and alpha 6 integrin-dependent cellular morphology. J Cell Biol 158: 1299-1309.
160. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, et al. (2009). Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49: 491-503.
161. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB, et al. (2011). CD151 amplifies signaling by integrin alpha 6 beta 1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology 140: 1629-1641.
162. Kischel P, Bellahcene A, Deux B, Lamour V, Dobson R, De Pauw E, et al. (2012). Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Res 32: 5211-5220.
163. Kitadokoro K, Bordo D, Galli G, Petracca R, Falugi F, Abrignani S, et al. (2001). CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J 20: 12-18.
164. Klein-Soyer C, Azorsa DO, Cazenave J-P, Lanza F, (2000). CD9 participates in endothelial cell migration during in vitro wound repair. Arterioscler Thromb Vasc Biol 20: 360-369.
165. Klosek SK, Nakashiro K, Hara S, Shintani S, Hasegawa H, Hamakawa H, (2005). CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochem Biophys Res Commun 336: 408-416.
166. Klosek SK, Nakashiro K, Hara S, Goda H, Hasegawa H, Hamakawa H, (2009). CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. Biochem Biophys Res Commun 379: 1097-1100.
167. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, et al. (1994). Differential expression of extracellular-matrix molecules and the alpha(6)-integrins in the normal and neoplastic prostate. Am J Pathol 145: 167-174.
168. Kobayashi H, Hosono O, Iwata S, Kawasaki H, Kuwana M, Tanaka H, et al. (2004). The tetraspanin CD9 is preferentially expressed on the human CD4(+)CD45RA(+) naive T cell population and is involved in T cell activation. Clin Exp Immunol 137: 101-108.
169. Kohmo S, Kijima T, Otani Y, Mori M, Minami T, Takahashi R, et al. (2010). Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res 70: 8025-8035.
170. Kohno M, Hasegawa H, Miyake M, Yamamoto T, Fujita S, (2002). CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int J Cancer 97: 336-343.
171. Kotha J, Longhurst C, Appling W, Jennings LK, (2008). Tetraspanin CD9 regulates β1 integrin activation and enhances cell motility to fibronectin via a PI-3 kinase-dependent pathway. Exp Cell Res 314: 1811-1822.
172. Kovalenko OV, Metcalf DG, DeGrado WF, Hemler ME, (2005). Structural organization and interactions of transmembrane domains in tetraspanin proteins. BMC Struct Biol 5. doi: 10.1186-1472-6807-5-11.
173. Kubista B, Erovic BM, Klinger H, Sulzbacher I, Trieb K, (2004). CD9 expression is not a prognostic factor in human osteosarcoma. Cancer Lett 209: 105-110.
174. Kusukawa J, Ryu F, Kameyama T, Mekada E, (2001). Reduced expression of CD9 in oral squamous cell carcinoma: CD9 expression inversely related to high prevalence of lymph node metastasis. J Oral Pathol Med 30: 73-79.
175. Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, et al. (2012). Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer 106: 923-930.
176. Kwon MS, Shin S-H, Yim S-H, Lee KY, Kang H-M, Kim T-M, et al. (2007). CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung. Lung Cancer 57: 46-53.
177. Lafleur MA, Xu D, Hemler ME, (2009). Tetraspanin proteins regulate membrane type-1 matrix metalloproteinase-dependent pericellular proteolysis. Mol Biol Cell 20: 2030-2040.
178. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, et al. (2002). Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 270: 211-226.
179. Lan RF, Liu ZX, Liu XC, Song YE, Wang DW, (2005). CD151 promotes neovascularization and improves blood perfusion in a rat hind-limb ischemia model. J Endovasc Ther 12: 469-478.
180. Lawrence MG, Veveris-Lowe TL, Whitbread AK, Nicol DL, Clements JA, (2007). Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases. Cells Tissues Organs 185: 111-115.
181. Lee HA, Park I, Byun HJ, Jeoung D, Kim YM, Lee H, (2011). Metastasis suppressor KAI1/CD82 attenuates the matrix adhesion of human prostate cancer cells by suppressing fibronectin expression and beta(1) Integrin activation. Cell Physiol Biochem 27: 575-586.
182. Lee JM, Dedhar S, Kalluri R, Thompson EW, (2006). The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981.
183. Levy S, Shoham T, (2005). Protein-protein interactions in the tetraspanin web. Physiology 20: 218-224.
184. Levy S, Todd SC, Maecker HT, (1998). CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 16: 89-109.
185. Li JJ, Xu M, Huang HP, Zhou JJ, Abdel-Halim ES, Zhang JR, et al. (2011). Aptamer-quantum dots conjugates-based ultrasensitive competitive electrochemical cytosensor for the detection of tumor cell. Talanta 85: 2113-2120.
186. Li Q, Yang XH, Xu F, Sharma C, Wang HX, Knoblich K, et al. (2012). Tetraspanin CD151 plays a key role in skin squamous cell carcinoma. Oncogene 32: 1772-1778.
187. Lijovic M, Somers G, Frauman AG, (2002). KAI1/CD82 protein expression in primary prostate cancer and in BPH associated with cancer. Cancer Detect Prev 36: 69-77.
188. Lin PC, Lin SC, Lee CT, Lin YJ, Lee JC, (2011). Dynamic change of tetraspanin CD151 membrane protein expression in colorectal cancer patients. Cancer Invest 29: 542-547.
189. Liu L, Liu WM, Zhou D, Cox J, Zhang XA, (2007). Tetraspanin CD151 promotes cell migration through regulating integrin trafficking. J Biol Chem 282: 31631-31642.
190. Liu WM, Zhang F, Moshiach S, Zhou B, Huang C, Srinivasan K, et al. (2012). Tetraspanin CD82 inhibits protrusion and retraction in cell movement by attenuating the plasma membrane-dependent actin organization. PLoS ONE 7: e51797.
191. Longo N, Yanez-Mo M, Mittelbrunn M, De La Rosa G, Munoz M, Sanchez-Madrid F, et al. (2001). Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 98: 3717-3726.
192. Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, et al. (2008). Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 14: 4526-4531.
193. Maecker HT, Todd SC, Levy S, (1997). The tetraspanin superfamily: molecular facilitators. FASEB J 11: 428-442.
194. Maeda K, Matsuhashi S, Hori K, Xin Z, Mukai T, Tabuchi K, et al. (1998). Cloning and characterization of a novel human gene, TM4SF6, encoding a protein belonging to the transmembrane 4 superfamily, and mapped to Xq22. Genomics 52: 240-242.
195. Majumder M, Tutunea-Fatan E, Xin X, Rodriguez-Torres M, Torres-Garcia J, Wiebe R, et al. (2012). Co-expression of α9β1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN. PLoS ONE 7: e35094.
196. Majumder P, Gomes K, Ulrich H, (2009). Aptamers: from bench side research towards patented molecules with therapeutic applications. Expert Opin Ther Pat 19: 1603-1613.
197. Mathivanan S, Fahner CJ, Reid GE, Simpson RJ, (2011). ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res 40: D1241-D1244.
198. Mazzocca A, Liotta F, Carloni V, (2008). Tetraspanin CD81-regulated cell motility plays a critical role in intrahepatic metastasis of hepatocellular carcinoma. Gastroenterology 135: 244-256.e241.
199. Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R, et al. (2001). Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 7: 81-88.
200. Mercurio AM, Rabinovitz I, Shaw LM, (2001). The α6b4 integrin and epithelial cell migration. Curr Opin Cell Biol 13: 541-545.
201. Metzelaar MJ, Schuurman HJ, Heijnen HF, Sixma JJ, Nieuwenhuis HK, (1991). Biochemical and immunohistochemical characteristics of CD62 and CD63 monoclonal antibodies. Expression of GMP-140 and LIMP-CD63 (CD63 antigen) in human lymphoid tissues. Virchows Arch B Cell Pathol Incl Mol Pathol 61: 269-277.
202. Mhawech P, Dulguerov P, Tschanz E, Verdan C, Ares C, Allal AS, (2003). Motility-related protein-1 (MRP-1//CD9) expression can predict disease-free survival in patients with squamous cell carcinoma of the head and neck. Br J Cancer 90: 471-475.
203. Min G, Wang H, Sun TT, Kong XP, (2006). Structural basis for tetraspanin functions as revealed by the cryo-EM structure of uroplakin complexes at 6-A resolution. J Cell Biol 173: 975-983.
204. Mitchell K, Szekeres C, Milano V, Svenson KB, Nilsen-Hamilton M, Kreidberg JA, et al. (2009). Alpha 3 beta 1 integrin in epidermis promotes wound angiogenesis and keratinocyte-to-endothelial-cell crosstalk through the induction of MRP3. J Cell Sci 122: 1778-1787.
205. Mitchell K, Svenson KB, Longmate WM, Gkirtzimanaki K, Sadej R, Wang XH, et al. (2010). Suppression of integrin alpha 3 beta 1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells. Cancer Res 70: 6359-6367.
206. Miyamoto S, Maruyama A, Okugawa K, Akazawa K, Baba H, Maehara Y, et al. (2001). Loss of motility-related protein 1 (MRP1/CD9) and integrin α3 expression in endometrial cancers. Cancer 92: 542-548.
207. Molday RS, Warren R, Loewen C, Molday L, (1999). Cyclic GMP-gated channel and peripherin/rds-rom-1 complex of rod cells. Novartis Found Symp 224: 249-261.
208. Mosig RA, Li L, Senturk E, Shah H, Huang F, Schlosshauer P, et al. (2012). Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer. J Ovarian Res 5: 1-9.
209. Nabokina SM, Senthilkumar SR, Said HM, (2011). Tspan-1 interacts with the thiamine transporter-1 in human intestinal epithelial cells and modulates its stability. Am J Physiol Gastrointest Liver Physiol 301: G808-G813.
210. Nagao K, Oka K, (2011). HIF-2 directly activates CD82 gene expression in endothelial cells. Biochem Biophys Res Commun 407: 260-265.
211. Nakagawa S, Arai Y, Mori H, Matsushita Y, Kubo T, Nakanishi T, (2009). Small interfering RNA targeting CD81 ameliorated arthritis in rats. Biochem Biophys Res Commun 388: 467-472.
212. Nakamoto T, Murayama Y, Oritani K, Boucheix C, Rubinstein E, Nishida M, et al. (2009). A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol 44: 889-896.
213. Nakamura Y, Handa K, Iwamoto R, Tsukamoto T, Takahasi M, Mekada E, (2001). Immunohistochemical distribution of CD9, heparin binding epidermal growth factor-like growth factor, and integrin α3β1 in normal human tissues. J Histochem Cytochem 49: 439-444.
214. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M, et al. (2010). Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 70: 1668-1678.
215. Ng T, Shima D, Squire A, Bastiaens PIH, Gschmeissner S, Humphries MJ, et al. (1999). PKC alpha regulates beta 1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J 18: 3909-3923.
216. Nicholson RH, Pantano S, Eliason JF, Galy A, Weiler S, Kaplan J, et al. (2000). Phemx, a novel mouse gene expressed in hematopoietic cells maps to the imprinted cluster on distal chromosome 7. Genomics 68: 13-21.
217. Nikopoulos K, Gilissen C, Hoischen A, Erik van Nouhuys C, Boonstra FN, Blokland EAW, et al. (2010). Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy. Am J Hum Genet 86: 240-247.
218. Nishiuchi R, Sanzen N, Nada S, Sumida Y, Wada Y, Okada M, et al. (2005). Potentiation of the ligand-binding activity of integrin alpha 3 beta 1 via association with tetraspanin CD151. Proc Natl Acad Sci U S A 102: 1939-1944.
219. Nojima Y, Hirose T, Tachibana K, Tanaka T, Shi L, Doshen J, et al. (1993). The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T cell activation and adhesion. Cell Immunol 152: 249-260.
220. Okazaki T, Ni A, Ayeni OA, Baluk P, Yao LC, Vossmeyer D, et al. (2009). α5β1 integrin blockade inhibits lymphangiogenesis in airway inflammation. Am J Pathol 174: 2378-2387.
221. Olweus J, Lund-Johansen F, Horejsi V, (1993). CD53, a protein with four membrane-spanning domains, mediates signal transduction in human monocytes and B cells. J Immunol 151: 707-716.
222. Oommen S, Gupta SK, Vlahakis NE, (2011). Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin {alpha}9{beta}1: identification of a specific {alpha}9{beta}1 binding site. J Biol Chem 286: 1083-1092.
223. Oren R, Takahashi S, Doss C, Levy R, Levy S, (1990). TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 10: 4007-4015.
224. Paiva B, Gutierrez NC, Chen X, Vidriales MB, Montalban MA, Rosinol L, et al. (2012). Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 26: 1862-1869.
225. Palmer TD, Ashby WJ, Lewis JD, Zijlstra A, (2011). Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev 63: 568-581.
226. Pardee JD, (2009). The actin cytoskeleton in cell motility, cancer, and infection. Colloquium Series on the Cell Biology of Medicine 1: 1-57.
227. Penas PF, Garcia-Diez A, Sanchez-Madrid F, Yanez-Mo M, (2000). Tetraspanins are localized at motility-related structures and involved in normal human keratinocyte wound healing migration. J Invest Dermatol 114: 1126-1135.
228. Petersen SH, Odintsova E, Haigh TA, Rickinson AB, Taylor GS, Berditchevski F, (2011). The role of tetraspanin CD63 in antigen presentation via MHC class II. Eur J Immunol 41: 2556-2561.
229. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. (1998). Binding of hepatitis C virus to CD81. Science 282: 938-941.
230. Powner D, Kopp PM, Monkley SJ, Critchley DR, Berditchevski F, (2011). Tetraspanin CD9 in cell migration. Biochem Soc Trans 39: 563-567.
231. Protty MB, Watkins NA, Colombo D, Thomas SG, Heath VL, Herbert JMJ, et al. (2009). Identification of Tspan9 as a novel platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin microdomains. Biochem J 417: 391-400.
232. Prox J, Willenbrock M, Weber S, Lehmann T, Schmidt-Arras D, Schwanbeck R, et al. (2012). Tetraspanin15 regulates cellular trafficking and activity of the ectodomain sheddase ADAM10. Cell Mol Life Sci 69: 2919-2932.
233. Puls KL, Ni J, Liu D, Morahan G, Wright MD, (1999). The molecular characterisation of a novel tetraspanin protein, TM4-B. Biochim Biophys Acta 1447: 93-99.
234. Qiong Z, Li X, Zhulin Y, Fang L, Leping Y, Xiongying M, (2012). Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder. World J Surg Oncol 10: 92-98.
235. Radford KJ, Thorne RF, Hersey P, (1996). CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with β1 integrins in human melanoma. Biochem Biophys Res Commun 222: 13-18.
236. Radford KJ, Thorne RF, Hersey P, (1997). Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. J Immunol 158: 3353-3358.
237. Richardson M, Jennings LK, Zhang X, (2011). Tetraspanins and tumor progression. Clin Exp Metastasis 28: 261-270.
238. Robb L, Tarrant J, Groom J, Ibrahim M, Li R, Borobakas B, et al. (2001). Molecular characterisation of mouse and human TSSC6: evidence that TSSC6 is a genuine member of the tetraspanin superfamily and is expressed specifically in haematopoietic organs. Biochim Biophys Acta 1522: 31-41.
239. Rockey WM, Hernandez FJ, Huang S-Y, Cao S, Howell C, (2011). Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther 21: 299-314.
240. Rorive S, Lopez XM, Maris C, Trepant A-L, Sauvage S, Sadeghi N, et al. (2010). TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas. Mod Pathol 23: 1418-1428.
241. Rubinstein E, Ziyyat A, Wolf J-P, Le Naour F, Boucheix C, (2006). Review: the molecular players of sperm-egg fusion in mammals. Semin Cell Dev Biol 17: 254-263.
242. Sachs N, Kreft M, Weerman MAV, Beynon AJ, Peters TA, Weening JJ, et al. (2006). Kidney failure in mice lacking the tetraspanin CD151. J Cell Biol 175: 33-39.
243. Sadej R, Romanska H, Baldwin G, Gkirtzimanaki K, Novitskaya V, Filer AD, et al. (2009). CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res 7: 787-798.
244. Sadej R, Romanska H, Kavanagh D, Baldwin G, Takahashi T, Kalia N, et al. (2010). Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res 70: 6059-6070.
245. Sagi Y, Landrigan A, Levy R, Levy S, (2012). Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81. Proc Natl Acad Sci U S A 109: 1613-1618.
246. Santra S, Malhotra A, (2011). Fluorescent nanoparticle probes for imaging of cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol 3: 501-510.
247. Sauer G, Kurzeder C, Grundmann R, Kreienberg R, Zeillinger R, Deissler H, (2003a). Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. Oncol Rep 10: 405-410.
248. Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R, Deissler H, (2003b). Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 9: 6426-6431.
249. Savagner P, (2001). Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 23: 912-923.
250. Schindl M, Birner P, Breitenecker G, Oberhuber G, (2001). Downregulation of KAI1 metastasis suppressor protein is associated with a dismal prognosis in epithelial ovarian cancer. Gynecol Oncol 83: 244-248.
251. Scholz C-J, Kurzeder C, Koretz K, Windisch J, Kreienberg R, Sauer G, et al. (2009). Tspan-1 is a tetraspanin preferentially expressed by mucinous and endometrioid subtypes of human ovarian carcinomas. Cancer Lett 275: 198-203.
252. Schroder HM, Hoffmann SC, Hecker M, Korff T, Ludwig T, (2013). The tetraspanin network modulates MT1-MMP cell surface trafficking. Int J Biochem Cell Biol 45: 1133-1144.
253. Seigneuret M, Delaguillaumie A, Lagaudriere-Gesbert C, Conjeaud H, (2001). Structure of the tetraspanin main extracellular domain-a partially conserved fold with a structurally variable domain insertion. J Biol Chem 276: 40055-40064.
254. Seigneuric R, Gobbo J, Colas P, Garrido C, (2011). Targeting cancer with peptide aptamers. Oncotarget 2: 557-561.
255. Serru V, Le Naour F, Billard M, Azorsa DO, Lanza F, Boucheix C, et al. (1999). Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions. Biochem J 340 (Pt 1): 103-111.
256. Serru V, Dessen P, Boucheix C, Rubinstein E, (2000). Sequence and expression of seven new tetraspans. Biochim Biophys Acta 1478: 159-163.
257. Setoguchi T, Kikuchi H, Yamamoto M, Baba M, Ohta M, Kamiya K, et al. (2011). Microarray analysis identifies versican and CD9 as potent prognostic markers in gastric gastrointestinal stromal tumors. Cancer Sci 102: 883-889.
258. Shariat AF, Karam JA, Margulis V, Karakiewicz PI, (2007). New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int 101: 675-683.
259. Shi GM, Ke AW, Zhou JA, Wang XY, Xu Y, Ding ZB, et al. (2010). CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology 52: 183-196.
260. Shigeta M, Sanzen N, Ozawa M, Gu J, Hasegawa H, Sekiguchi K, (2003). CD151 regulates epithelial cell-cell adhesion through PKC- and Cdc42-dependent actin cytoskeletal reorganization. J Cell Biol 163: 165-176.
261. Shih Y-CT, Elting LS, Pavluck AL, Stewart A, Halpern MT, (2010). Immunotherapy in the initial treatment of newly diagnosed cancer patients: utilization trend and cost projections for non-Hodgkin's lymphoma, metastatic breast cancer, and metastatic colorectal cancer. Cancer Invest 28: 46-53.
262. Sho M, Adachi M, Taki T, Hashida H, Konishi T, Huang C, et al. (1998). Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 79: 509-516.
263. Si Z, Hersey P, (1993). Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Int J Cancer 54: 37-43.
264. Simpson RJ, Lim JWE, Moritz RL, Mathivanan S, (2009). Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6: 267-283.
265. Sincock PM, Mayrhofer G, Ashman LK, (1997). Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63 and α5β1 integrins. J Histochem Cytochem 45: 515-525.
266. Sincock PM, Fitter S, Parton RG, Berndt MC, Gamble JR, Ashman LK, (1999). PETA-3/CD151, a member of the transmembrane 4 superfamily, is localised to the plasma membrane and endocytic system of endothelial cells, associates with multiple integrins and modulates cell function. J Cell Sci 112: 833-844.
267. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
268. Slupsky JR, Seehafer JG, Tang SC, Masellis-Smith A, Shaw AR, (1989). Evidence that monoclonal antibodies against CD9 antigen induce specific association between CD9 and the platelet glycoprotein IIb-IIIa complex. J Biol Chem 264: 12289-12293.
269. Soontornworajit B, Zhou J, Snipes MP, Battig MR, Wang Y, (2011). Affinity hydrogels for controlled protein release using nucleic acid aptamers and complementary oligonucleotides. Biomaterials 32: 6839-6849.
270. Sordat I, Decraene C, Silvestre T, Petermann O, Auffray C, Piétu G, et al. (2002). Complementary DNA arrays identify CD63 tetraspanin and α3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells. Lab Invest 82: 1715-1724.
271. Soyuer S, Soyuer I, Unal D, Ucar K, Yildiz OG, Orhan O, (2010). Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy. Pathol Res Pract 206: 607-610.
272. van Spriel AB, Figdor CG, (2010). The role of tetraspanins in the pathogenesis of infectious diseases. Microbes Infect 12: 106-112.
273. van Spriel AB, Puls KL, Sofi M, Pouniotis D, Hochrein H, Orinska Z, et al. (2004). A regulatory role for CD37 in T cell proliferation. J Immunol 172: 2953-2961.
274. Sridhar SC, Miranti CK, (2006). Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 25: 2367-2378.
275. Stehn JR, Schevzov G, O'Neill GM, Gunning PW, (2006). Specialisation of the tropomyosin composition of actin filaments provides new potential targets for chemotherapy. Curr Cancer Drug Targets 6: 245-256.
276. Sterk LM, Geuijen CAW, Van Den Berg JG, Claessen N, Weening JJ, Sonnenberg A, (2002). Association of the tetraspanin CD151 with the laminin-binding integrins {alpha}3{beta}1, {alpha}6{beta}1, {alpha}6{beta}4 and {alpha}7{beta}1 in cells in culture and in vivo. J Cell Sci 115: 1161-1173.
277. Stipp CS, (2010). Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev Mol Med 12. doi: 10.1017/S1462399409001355.
278. Stipp CS, Kolesnikova TV, Hemler ME, (2003a). EWI-2 regulates α3β1 integrin-dependent cell functions on laminin-5. J Cell Biol 163: 1167-1177.
279. Stipp CS, Kolesnikova TV, Hemler ME, (2003b). Functional domains in tetraspanin proteins. TRENDS Biochem Sci 28: 106-112.
280. Stupack DG, Cheresh DA, (2004). Integrins and angiogenesis. Curr Top Dev Biol 64: 207-238.
281. Sugiura T, Berditchevski F, (1999). Function of α3β1-tetraspanin protein conplexes in tumor cell invasion: evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol 146: 1375-1389.
282. Suzuki S, Miyazaki T, Tanaka N, Sakai M, Sano A, Inose T, et al. (2011). Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness. Ann Surg Oncol 18: 888-893.
283. Tachibana I, Bodorova J, Berditchevski F, Zutter MM, Hemler ME, (1997). NAG-2, a novel transmembrane-4 superfamily (TM4SF) protein that complexes with integrins and other TM4SF proteins. J Biol Chem 272: 29181-29189.
284. Tai XG, Yashiro Y, Abe R, Toyooka K, Wood CR, Morris J, et al. (1996). A role for CD9 molecules in T cell activation. J Exp Med 184: 753-758.
285. Takagi S, Fujikawa K, Imai T, Fukuhara N, Fukudome K, Minegishi M, et al. (1995). Identification of a highly specific surface marker of T-cell acute lymphoblastic leukemia and neuroblastoma as a new member of the transmembrane 4 superfamily. Int J Cancer 61: 706-715.
286. Takahashi M, Sugiura T, Abe M, Ishii K, Shirasuna K, (2007). Regulation of c-Met signaling by the tetraspanin KAI-1/CD82 affects cancer cell migration. Int J Cancer 121: 1919-1929.
287. Takeda Y, Kazarov AR, Butterfield CE, Hopkins BD, Benjamin LE, Kaipainen A, et al. (2007). Deletion of tetraspanin CD151 results in decreased pathological angiogenesis in vivo and in vitro. Blood 109: 1524-1532.
288. Takeda Y, Li QL, Kazarov AR, Epardaud M, Elpek K, Turley SJ, et al. (2011). Diminished metastasis in tetraspanin CD151-knockout mice. Blood 118: 464-472.
289. Takino T, Miyamori H, Kawaguchi N, Uekita T, Seiki M, Sato H, (2003). Tetraspanin CD63 promotes targeting and lysosomal proteolysis of membrane-type 1 matrix metalloproteinase. Biochem Biophys Res Commun 304: 160-166.
290. Tan W, Wang H, Chen Y, Zhang X, Zhu H, (2011). Molecular aptamers for drug delivery. Trends Biotechnol 29: 634-640.
291. Tarrant JM, Groom J, Metcalf D, Li R, Borobokas B, Wright MD, et al. (2002). The absence of Tssc6, a member of the tetraspanin superfamily, does not affect lymphoid development but enhances in vitro T-cell proliferative responses. Mol Cell Biol 22: 5006-5018.
292. Taylor DD, Gercel-Taylor C, (2011). Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol 33: 441-454.
293. Tejera E, Rocha-Perugini V, Lõpez-Martín S, Pérez-Hernández D, Bachir AI, Horwitz AR, et al. (2013). CD81 regulates cell migration through its association with Rac GTPase. Mol Biol Cell 24: 261-273.
294. Terada N, Baracskay K, Kinter M, Melrose S, Brophy PJ, Boucheix C, et al. (2002). The tetraspanin protein, CD9, is expressed by progenitor cells committed to oligodendrogenesis and is linked to β1 integrin, CD81, and Tspan-2. Glia 40: 350-359.
295. Terracciano S, Bruno I, D'Amico E, Bifulco G, Zampella A, Sepe V, et al. (2008). Synthetic and pharmacological studies on new simplified analogues of the potent actin-targeting Jaspamide. Bioorg Med Chem 16: 6580-6588.
296. Testa JE, Brooks PC, Lin J, Quigley JP, (1999). Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res 59: 3812-3820.
297. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, et al. (2001). Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 166: 7309-7318.
298. Thery C, Zitvogel L, Amigorena S, (2002). Exosomes: composition, biogenesis and function. Nat Rev Immunol 2: 569-579.
299. Thiolloy S, Rinker-Schaeffer CW, (2011). Thinking outside the box: using metastasis suppressors as molecular tools. Semin Cancer Biol 21: 89-98.
300. Timoshenko AV, Rastogi S, Lala PK, (2007). Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer 97: 1090-1098.
301. Tiwari-Woodruff SK, Kaplan R, Kornblum HI, Bronstein JM, (2004). Developmental expression of OAP-1/Tspan-3, a member of the tetraspanin superfamily. J Neurosci Res 77: 166-173.
302. Todd SC, Doctor VS, Levy S, (1998). Sequences and expression of six new members of the tetraspanin/TM4SF family. Biochim Biophys Acta 1399: 101-104.
303. Tokuhara T, Hasegawa H, Hattori N, Ishida H, Taki T, Tachibana S, et al. (2001). Clinical significance of CD151 gene expression in non-small cell lung cancer. Clin Cancer Res 7: 4109-4114.
304. Traggiai E, Lunardi C, Bason C, Dolcino M, Tinazzi E, Corrocher R, et al. (2010). Generation of anti-NAG-2 mAb from patients' memory B cells: implications for a novel therapeutic strategy in systemic sclerosis. Int Immunol 22: 367-374.
305. Travis GH, Christerson L, Danielson PE, Klisak I, Sparkes RS, Hahn LB, et al. (1991). The human retinal degeneration slow (RDS) gene: chromosome assignment and structure of the mRNA. Genomics 10: 733-739.
306. Tuerk C, Gold L, (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
307. Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M, et al. (1999). Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 79: 1168-1173.
308. Veenbergen S, van Spriel AB, (2011). Tetraspanins in the immune response against cancer. Immunol Lett 138: 129-136.
309. Velling T, Nilsson S, Stefansson A, Johansson S, (2004). β1-integrins induce phosphorylation of Akt on serine473 independently of focal adhesion kinase and Src family kinases. EMBO Rep 5: 901-905.
310. Vlahakis NE, Young BA, Atakilit A, Hawkridge AE, Issaka RB, Boudreau N, et al. (2007). Integrin alpha 9 beta 1 directly binds to vascular endothelial growth factor (VEGF)- a and contributes to VEGF-A-induced angiogenesis. J Biol Chem 282: 15187-15196.
311. Voss MA, Gordon N, Maloney S, Ganesan R, Ludeman L, McCarthy K, et al. (2011). Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Br J Cancer 104: 1611-1618.
312. Wall SJ, Jiang Y, Muschel RJ, DeClerck YA, (2003). Meeting report: proteases, extracellular matrix, and cancer: an AACR special conference in cancer research. Cancer Res 63: 4750-4755.
313. Wang GL, Chen L, Wei YZ, Zhou JM, Wu YY, Zhang YX, et al. (2012). The effect of NET-1 on the proliferation, migration and endocytosis of the SMMC-7721 HCC cell line. Oncol Rep 27: 1944-1952.
314. Wang L, Liu L, Che Y, Wang L, Jiang L, Dong C, et al. (2010). Egress of HSV-1 capsid requires the interaction of VP26 and a cellular tetraspanin membrane protein. Virol J 7: 156-156.
315. Wang XW, Ferreira AM, Shao Q, Laird DW, Sandig M, (2005). beta 3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells. Prostate 63: 65-80.
316. Wei QA, Huang XL, Lin JY, Fei YJ, Liu ZX, Zhang XA, (2011). Adeno associated viral vector-delivered and hypoxia response element-regulated CD151 expression in ischemic rat heart. Acta Pharmacol Sin 32: 201-208.
317. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J, (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409.
318. Wells A, (2006). Cell motility in cancer invasion and metastasis. In:, Wells A, (ed.). Cancer Metastasis-Biology and Treatment, 1st edn, Vol. 8. Springer: Dordrecht, The Netherland, pp. 1-351.
319. Winterwood NE, Varzavand A, Meland MN, Ashman LK, Stipp CS, (2006). A critical role for tetraspanin CD151 in α3β1 and α6β4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell 17: 2707-2721.
320. Wistow G, Berstein SL, Wyatt MK, Farriss RN, Behal A, Touchman J, et al. (2002). Expressed sequence tag analysis of human RPE/choroid for the NEIBank Project: over 6000 non-redundant transcripts, novel genes and splice variants. Mol Vis 8: 205-220.
321. Woegerbauer M, Thurnher D, Houben R, Pammer J, Kloimstein P, Heiduschka G, et al. (2010). Expression of the tetraspanins CD9, CD37, CD63, and CD151 in Merkel cell carcinoma: strong evidence for a posttranscriptional fine-tuning of CD9 gene expression. Mod Pathol 23: 751-762.
322. Wright MD, Geary SM, Fitter S, Moseley GW, Lau L-M, Sheng K-C, et al. (2004a). Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol 24: 5978-5988.
323. Wright MD, Moseley GW, Van Spriel AB, (2004b). Tetraspanin microdomains in immune cell signalling and malignant disease. Tissue Antigens 64: 533-542.
324. Wuttig D, Zastrow S, Fussel S, Toma MI, Meinhardt M, Kalman K, et al. (2012). CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int J Cancer 131: E693-E704.
325. Xu D, Sharma C, Hemler ME, (2009). Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J 23: 3674-3681.
326. Yanez-Mo M, Barreiro O, Gonzalo P, Batista A, Megias D, Genis L, et al. (2008). MT1-MMP collagenolytic activity is regulated through association with tetraspanin CD151 in primary endothelial cells. Blood 112: 3217-3226.
327. Yáñez-Mõ M, Alfranca A, Cabanas C, Marazuela M, Tejedor R, Ursa MA, et al. (1998). Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/ PETA-3 with α3β1 integrin localized at endothelial lateral junctions. J Cell Biol 141: 791-804.
328. Yáñez-Mõ M, Mittelbrunn M, Sánchez-Madrid F, (2001). Tetraspanins and intercellular interactions. Microcirculation 8: 153-168.
329. Yáñez-Mõ M, Gutiérrez-Lõpez MD, Cabañas C, (2011). Functional interplay between tetraspanins and proteases. Cell Mol Life Sci 68: 3323-3335.
330. Yang X, Claas C, Kraeft S-K, Chen LB, Wang Z, Kreidberg JA, et al. (2002). Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology. Mol Biol Cell 13: 767-781.
331. Yang XWH, Richardson AL, Torres-Arzayus MI, Zhou PC, Sharma C, Kazarov AR, et al. (2008). CD151 accelerates breast cancer by regulating alpha(6) integrin function, signaling, and molecular organization. Cancer Res 68: 3204-3213.
332. Yang XWH, Flores LM, Li QL, Zhou PC, Xu FH, Krop IE, et al. (2010). Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 70: 2256-2263.
333. Yang YM, Zhang ZW, Liu QM, Sun YF, Yu JR, Xu WX, (2013). Overexpression of CD151 predicts prognosis in patients with resected gastric cancer. PLoS ONE 8: e58990. doi: 10.1371/journal.pone.0058990.
334. Yauch RL, Berditchevski F, Harler MB, Reichner J, Hemler ME, (1998). Highly stoichiometric, stable, and specific association of integrin α3β1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. Mol Biol Cell 9: 2751-2765.
335. Yoo SH, Lee K, Chae JY, Moon KC, (2011). CD151 expression can predict cancer progression in clear cell renal cell carcinoma. Histopathology 58: 191-197.
336. Yu C, Hu Y, Duan J, Yuan W, Wang C, Xu H, et al. (2011). Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS ONE 6: e24077. doi: 10.1371/journal.pone.0024077.
337. Yu J, Lin JH, Wu XR, Sun TT, (1994). Uroplakins Ia and Ib, two major differentiation products of bladder epithelium, belong to a family of four transmembrane domain (4TM) proteins. J Cell Biol 125: 171-182.
338. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S, (2011). Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 7: 2241-2249.
339. Zemni R, Bienvenu T, Vinet MC, Sefiani A, Carrié A, Billuart P, et al. (2000). A new gene involved in X-linked mental retardation identified by analysis of an X;2 balanced translocation. Nat Genet 24: 167-170.
340. Zhang F, Michaelson JE, Moshiach S, Sachs N, Zhao W, Sun Y, et al. (2011a). Tetraspanin CD151 maintains vascular stability by balancing the forces of cell adhesion and cytoskeletal tension. Blood 118: 4274-4284.
341. Zhang JS, Gong A, Young CYF, (2007). ZNF185, an actin-cytoskeleton-associated growth inhibitory LIM protein in prostate cancer. Oncogene 26: 111-122.
342. Zhang XA, Bontrager AL, Christopher SS, Stine-Kathrein K, Bazzoni G, Chen LB, et al. (2001a). Phosphorylation of a conserved integrin α3 QPSXXE motif regulates signaling, motility, and cytoskeletal engagement. Mol Biol Cell 12: 351-365.
343. Zhang XA, Bontrager AL, Hemler ME, (2001b). Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PKC to specific beta1 integrins. J Biol Chem 276: 25005-25013.
344. Zhang XA, Kazarov AR, Yang X, Bontrager AL, Stipp CS, Hemler ME, (2002). Function of the tetraspanin CD151-a6b1 integrin complex during cellular morphogenesis. Mol Biol Cell 13: 1-11.
345. Zhang XA, Lane WS, Charrin S, Rubinstein E, Liu L, (2003). EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells. Cancer Res 63: 2665-2674.
346. Zhang Y, Hong H, Cai W, (2011b). Tumor-targeted drug delivery with aptamers. Curr Med Chem 18: 4185-4194.
347. Zhang ZY, Zhang LJ, Hua YQ, Jia XF, Li JA, Hu S, et al. (2010). Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines. BMC Cancer 10: 206. doi: 10.1186/1471-2407-10-206.
348. Zheng R, Yano SJ, Zhang HL, Nakataki E, Tachibana I, (2005). CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice. Oncol Res 15: 365-372.
349. Zheng Z, Liu Z, (2007a). Activation of the phosphatidylinositol 3-kinase/protein kinase akt pathway mediates CD151-induced endothelial cell proliferation and cell migration. Int J Biochem Cell Biol 39: 340-348.
350. Zheng Z, Liu ZX, (2007b). CD151 gene delivery increases eNOS activity and induces ECV304 migration, proliferation and tube formation. Acta Pharmacol Sin 28: 66-72.
351. Zheng ZZ, Liu ZX, (2006). CD151 gene delivery activates PI3K/Akt pathway and promotes neovascularization after myocardial infarction in rats. Mol Med 12: 214-220.
352. Zhijun X, Shulan Z, Zhuo Z, (2007). Expression and significance of the protein and mRNA of metastasis suppressor gene Me491/cd63 and integrin α5 in ovarian cancer tissues. Eur J Gynaecol Oncol 28: 179-183.
353. Zhou B, Liu L, Reddivari M, Zhang XA, (2004). The palmitoylation of metastasis suppressor KAI1/CD82 is important for its motility- and invasiveness-inhibitory activity. Cancer Res 64: 7455-7463.
354. Zhou Z, Ran YL, Hu H, Pan J, Li ZF, Chen LZ, et al. (2008). TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression. Clin Exp Metastasis 25: 537-548.
355. Zhu GH, Huang C, Qiu ZJ, Liu J, Zhang ZH, Zhao N, et al. (2011). Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci 56: 1090-1098.
356. Zijlstra A, Lewis J, DeGryse B, Stuhlmann H, Quigley JP, (2008). The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 13: 221-234.
357. Zitvogel L, Tesniere A, Kroemer G, (2006). Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715-727.
358. Zlatna R, Pamina Xenia Charlotte G, Peter H, Matthias K, Birgit L, Manfred S, et al. (2009). Tumor suppressor KAI1 affects integrin αvβ3-mediated ovarian cancer cell adhesion, motility, and proliferation. Exp Cell Res 315: 1759-1771.
359. Zuo HJ, Liu ZX, Liu XC, Yang J, Liu T, Wen S, et al. (2009a). Assessment of myocardial blood perfusion improved by CD151 in a pig myocardial infarction model. Acta Pharmacol Sin 30: 70-77.
360. Zuo HJ, Liu ZX, Liu XC, Yang J, Liu T, Wen S, et al. (2009b). CD151 gene delivery after myocardial Infarction promotes functional neovascularization and activates FAK signaling. Mol Med 15: 307-315.
361. Zuo HJ, Lin JY, Liu ZY, Liu WF, Liu T, Yang J, et al. (2010). Activation of the ERK signaling pathway is involved in CD151-induced angiogenic effects on the formation of CD151-integrin complexes. Acta Pharmacol Sin 31: 805-812.
362. Zvierev V, Wang JC, Chevrette M, (2005). Over-expression of CD9 does not affect in vivo tumorigenic or metastatic properties of human prostate cancer cells. Biochem Biophys Res Commun 337: 498-504.